Krystal Biotech, Inc. - Common Stock (KRYS)

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 16.54% on an annualized basis producing an average annual return of 31.18%. Currently, Krystal Biotech has a market capitalization of $4.73 billion.

The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data.

Krystal Biotech (KRYS) Q2 2025 earnings beat estimates with $96M revenue and $1.29 EPS, driven by VYJUVEK success. Shares rose 4% pre-market.

These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next